HRP20100039T1 - Nosač bioadhezivan za sluznicu za sporo oslobađanje aktivnih elemenata - Google Patents
Nosač bioadhezivan za sluznicu za sporo oslobađanje aktivnih elemenata Download PDFInfo
- Publication number
- HRP20100039T1 HRP20100039T1 HR20100039T HRP20100039T HRP20100039T1 HR P20100039 T1 HRP20100039 T1 HR P20100039T1 HR 20100039 T HR20100039 T HR 20100039T HR P20100039 T HRP20100039 T HR P20100039T HR P20100039 T1 HRP20100039 T1 HR P20100039T1
- Authority
- HR
- Croatia
- Prior art keywords
- agent
- bioadhesive
- carrier
- active element
- oral
- Prior art date
Links
- 239000000227 bioadhesive Substances 0.000 title claims abstract 15
- 239000000203 mixture Substances 0.000 claims abstract 13
- 229920000642 polymer Polymers 0.000 claims abstract 10
- 239000003085 diluting agent Substances 0.000 claims abstract 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract 4
- 239000008187 granular material Substances 0.000 claims abstract 4
- 238000002156 mixing Methods 0.000 claims abstract 4
- 239000011230 binding agent Substances 0.000 claims abstract 3
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- 210000004877 mucosa Anatomy 0.000 claims abstract 3
- 238000003825 pressing Methods 0.000 claims abstract 3
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract 2
- -1 alkali metal alkyl sulfate Chemical class 0.000 claims abstract 2
- 238000001035 drying Methods 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 10
- 210000004400 mucous membrane Anatomy 0.000 claims 6
- 239000003443 antiviral agent Substances 0.000 claims 5
- 229960004150 aciclovir Drugs 0.000 claims 4
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000003444 anaesthetic effect Effects 0.000 claims 3
- 230000000202 analgesic effect Effects 0.000 claims 3
- 230000003474 anti-emetic effect Effects 0.000 claims 3
- 239000002111 antiemetic agent Substances 0.000 claims 3
- 229940121375 antifungal agent Drugs 0.000 claims 3
- 239000003429 antifungal agent Substances 0.000 claims 3
- 230000003115 biocidal effect Effects 0.000 claims 3
- 239000001913 cellulose Substances 0.000 claims 3
- 229920002678 cellulose Polymers 0.000 claims 3
- 235000010980 cellulose Nutrition 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- 229940124641 pain reliever Drugs 0.000 claims 3
- 210000003296 saliva Anatomy 0.000 claims 3
- 208000001688 Herpes Genitalis Diseases 0.000 claims 2
- 208000009889 Herpes Simplex Diseases 0.000 claims 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 2
- 102000014171 Milk Proteins Human genes 0.000 claims 2
- 108010011756 Milk Proteins Proteins 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000004599 antimicrobial Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000013265 extended release Methods 0.000 claims 2
- 201000004946 genital herpes Diseases 0.000 claims 2
- 229960003943 hypromellose Drugs 0.000 claims 2
- 235000021239 milk protein Nutrition 0.000 claims 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 229920002261 Corn starch Polymers 0.000 claims 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 1
- 206010013911 Dysgeusia Diseases 0.000 claims 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 claims 1
- 208000005794 Hairy Leukoplakia Diseases 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 208000005647 Mumps Diseases 0.000 claims 1
- 208000007027 Oral Candidiasis Diseases 0.000 claims 1
- 208000007117 Oral Ulcer Diseases 0.000 claims 1
- 206010031009 Oral pain Diseases 0.000 claims 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims 1
- 208000026375 Salivary gland disease Diseases 0.000 claims 1
- 229920002385 Sodium hyaluronate Polymers 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 claims 1
- 208000005946 Xerostomia Diseases 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000002421 anti-septic effect Effects 0.000 claims 1
- 206010064097 avian influenza Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 229960001631 carbomer Drugs 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 229940105329 carboxymethylcellulose Drugs 0.000 claims 1
- 229940045110 chitosan Drugs 0.000 claims 1
- 239000008120 corn starch Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010013781 dry mouth Diseases 0.000 claims 1
- 229960002963 ganciclovir Drugs 0.000 claims 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims 1
- 208000018925 gastrointestinal mucositis Diseases 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 208000010805 mumps infectious disease Diseases 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- 206010030979 oral hairy leukoplakia Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 229940068984 polyvinyl alcohol Drugs 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 claims 1
- 229940010747 sodium hyaluronate Drugs 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 229940093257 valacyclovir Drugs 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
- 229960002555 zidovudine Drugs 0.000 claims 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims 1
- 230000006835 compression Effects 0.000 abstract 1
- 238000007906 compression Methods 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 238000009736 wetting Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
Abstract
Postupak za pripremu nosača bioadhezivnog za sluznicu sa sporim oslobađanjem, naznačen time što sadrži: a) miješanje najmanje jednog aktivnog elementa sa alkilsulfatom alkalnog metala i razblaživačem; b) vlaženje navedene smjese vezivnim sredstvom; c) sušenje i ujednačavanje navedene smjese; d) granulacija navedene smjese tako da se formiraju primarne granule; e) miješanje navedenih primarnih granula sa najmanje jednim bioadhezivnim polimerom i najmanje jednim polimerom za produženo oslobađanje i najmanje jednim sredstvom za prešanje; if) prešanje navedene smjese u e). Patent sadrži još 18 patentnih zahtjeva.
Claims (19)
1. Postupak za pripremu nosača bioadhezivnog za sluznicu sa sporim oslobađanjem, naznačen time što sadrži:
a) miješanje najmanje jednog aktivnog elementa sa alkilsulfatom alkalnog metala i razblaživačem;
b) vlaženje navedene smjese vezivnim sredstvom;
c) sušenje i ujednačavanje navedene smjese;
d) granulacija navedene smjese tako da se formiraju primarne granule;
e) miješanje navedenih primarnih granula sa najmanje jednim bioadhezivnim polimerom i najmanje jednim polimerom za produženo oslobađanje i najmanje jednim sredstvom za prešanje; i
f) prešanje navedene smjese u e).
2. Postupak prema patentnom zahtjevu 1, naznačen time što je navedeni najmanje jedan aktivni element – aktivni element topljiv u vodi i što je navedeni najmanje jedan razblaživač, netopljiv razblaživač.
3. Postupak prema patentnom zahtjevu 1 ili 2, naznačen time što je navedeni najmanje jedan aktivni element – netopljiv aktivni element i što je navedeni najmanje jedan razblaživač – razblaživač topljiv u vodi.
4. Postupak prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time što je vezivno sredstvo polivinilpirolidon.
5. Postupak prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time što najmanje jedan bioadhezivni polimer sadrži prirodne proteine izabrane iz grupe koju čine prirodni proteini mlijeka, karbomer, alginat, hitosan, ksantan guma, hidroksipropil celuloza, polivinilalkohol, karboksimetil celuloza, hidroksipropil metil celuloza, hidroksietil celuloza, natrij-hijaluronat, akrilni polimeri i njihove smjese.
6. Postupak prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time što je najmanje jedan polimer za produženo oslobađanje celulozni polimer ili derivat celuloznog polimera.
7. Postupak prema patentnom zahtjevu 6, naznačen time što je navedeni celulozni polimer - hipromeloza.
8. Postupak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time što je navedeni najmanje jedan aktivni element izabran iz grupe koju čine: antivirusno sredstvo, antigljivično sredstvo, analgetik, anestetik, sredstvo za ublažavanje bola, antiemetik, sredstvo koje stimulira lučenje pljuvačke, antiseptičko sredstvo, anti-inflamatorno sredstvo, antibiotik i njihove smjese.
9. Postupak prema patentnom zahtjevu 8, naznačen time što je najmanje jedan aktivni element spojen sa dodatnim aktivnim elementom koji je izabran iz grupe koju čine: antivirusno sredstvo, antigljivično sredstvo, analgetik, anestetik, sredstvo za ublažavanje bola, antiemetik, sredstvo koje stimulira lučenje pljuvačke, antiseptično sredstvo, anti-inflamatorno sredstvo, antibiotik i njihove smjese.
10. Nosač bioadhezivan za sluznicu sa sporim oslobađanjem koji se može dobiti pomoću postupka prema patentnom zahtjevu 1, naznačen time što sadrži 10 do 200 mg antivirusnog sredstva koji je izabran iz grupe koju čine aciklovir, valaciklovir, ganciklovir i zidovudin, 1 do 75 težinskih % mikrokristalne celuloze, 2 do 10 težinskih % natrij lauril sulfata i 0.5 do 5 težinskih % polivinilpirolidona i 10 do 40 težinskih % najmanje jednog bioadhezivnog polimera koji je izabran iz grupe koju čine prirodni proteini mlijeka i njihove smjese i 10% do 40 težinskih % hipromeloze.
11. Nosač bioadhezivan za sluznicu sa sporim oslobađanjem prema patentnom zahtjevu 10, naznačen time što je navedeno antivirusno sredstvo aciklovir.
12. Nosač bioadhezivan za sluznicu sa sporim oslobađanjem prema patentnom zahtjevu 11, naznačen time što je navedeni aciklovir prisutan u količini od 10 do 500 mg u navedenom nosaču.
13. Nosač bioadhezivan za sluznicu sa sporim oslobađanjem prema patentnom zahtjevu 11, naznačen time što je navedeni aciklovir prisutan u količini od 50 do 100 mg u navedenom nosaču.
14. Nosač bioadhezivan za sluznicu sa sporim oslobađanjem prema bilo kojem od patentnih zahtjeva 11 do 13, naznačen time što navedeni nosač ne sadrži laktozu i kukuruzni škrob.
15. Nosač bioadhezivan za sluznicu sa sporim oslobađanjem prema bilo kojem od patentnih zahtjeva 11 do 14, naznačen time što je najmanje jedan aktivni element povezan sa najmanje dva dodatna aktivna elementa koji su izabrani iz grupe koju čine: antivirusno sredstvo, antigljivično sredstvo, analgetik, anestetik, sredstvo za ublažavanje bola, antiemetik, sredstvo koje stimulira lučenje pljuvačke, antiseptično sredstvo, anti-inflamatorno sredstvo, antibiotik i njihove smjese.
16. Primjena nosača bioadhezivnog za sluznicu sa sporim oslobađanjem prema patentnom zahtjevu 10, naznačen time što se koristi za proizvodnju lijeka za liječenje bolesti sluznice.
17. Primjena prema patentnom zahtjevu 16, naznačena time što su bolesti sluznice –bolesti usne šupljine.
18. Primjena prema patentnom zahtjevu 17, naznačena time što su bolesti usne šupljine izabrane iz grupe koju čine: herpes simpleks kompleks 1 (HSV-1), genitalni herpes (HSV-2), oralni mukozitis, oralna kandidijaza, oralna dlakava leukoplakija, oralni čirevi, poremećaji pljuvačnih žlijezda, promjenjena oralna flora (smanjena bakterijska flora), poremećaj ukusa, periodontitis, kserostomija, gastrointestinalni mukozitis koji uzrokuje sekundarne promjene u oralnom statusu koji obuhvaća nepromjenjenu inflamaciju, higijenu i ishranu, kao i oralni bol.
19. Primjena nosača bioadhezivnog za mukozu sa sporim oslobađanjem prema patentnom zahtjevu 19, naznačen time što se za proizvodnju lijeka za liječenje herpes simpleks kompleksa 1 (HSV-1), genitalnog herpesa (HSV-2), infekcije varičela zoster virusom (VZV), Epstein-Barr virusom, humanim herpes virusom 8, ptičje gripe, zaušnjaka, HIV-a, infekcije respiratornim sincicijalnim virusom, gripe, parainfluence i infekcije citomegalovirusom.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06290480A EP1837020A1 (en) | 2006-03-24 | 2006-03-24 | Mucosal bioadhesive slow release carrier for delivering active principles |
PCT/IB2007/001662 WO2007110778A2 (en) | 2006-03-24 | 2007-03-23 | Mucosal bioadhesive slow release carrier for delivering active principles |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100039T1 true HRP20100039T1 (hr) | 2010-02-28 |
Family
ID=36889131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100039T HRP20100039T1 (hr) | 2006-03-24 | 2010-01-21 | Nosač bioadhezivan za sluznicu za sporo oslobađanje aktivnih elemenata |
Country Status (27)
Country | Link |
---|---|
US (5) | US20090169511A1 (hr) |
EP (3) | EP1837020A1 (hr) |
JP (1) | JP5242548B2 (hr) |
KR (1) | KR101335185B1 (hr) |
CN (1) | CN101410092B (hr) |
AR (1) | AR060085A1 (hr) |
AT (1) | ATE446743T1 (hr) |
AU (1) | AU2007231029B2 (hr) |
BR (1) | BRPI0709057C1 (hr) |
CA (1) | CA2647123C (hr) |
CY (1) | CY1109723T1 (hr) |
DE (1) | DE602007002996D1 (hr) |
DK (1) | DK1998750T3 (hr) |
ES (1) | ES2335712T3 (hr) |
HK (1) | HK1121692A1 (hr) |
HR (1) | HRP20100039T1 (hr) |
IL (1) | IL193987A (hr) |
ME (1) | ME01180B (hr) |
MX (1) | MX2008012186A (hr) |
MY (1) | MY150072A (hr) |
PL (1) | PL1998750T3 (hr) |
PT (1) | PT1998750E (hr) |
RS (1) | RS51342B (hr) |
RU (1) | RU2420267C2 (hr) |
SI (1) | SI1998750T1 (hr) |
WO (1) | WO2007110778A2 (hr) |
ZA (1) | ZA200807883B (hr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1837020A1 (en) | 2006-03-24 | 2007-09-26 | Bioalliance Pharma | Mucosal bioadhesive slow release carrier for delivering active principles |
EP2165706A1 (en) * | 2008-09-18 | 2010-03-24 | BioAlliance Pharma | Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers. |
EP2509586B1 (en) | 2009-12-09 | 2018-05-02 | Vectans Pharma | Mucoadhesive buccal tablets for the treatment of orofacial herpes |
EP2335690A1 (en) | 2009-12-09 | 2011-06-22 | BioAlliance Pharma | Mucoadhesive buccal tablets for the treatment of orofacial herpes |
US8592434B2 (en) * | 2009-12-09 | 2013-11-26 | Bioalliance Pharma Sa | Mucoadhesive buccal tablets for the treatment of orofacial herpes |
CA2841851A1 (en) * | 2011-07-15 | 2013-01-24 | Femalon S.P.R.L. | Composition and method for treating hpv |
KR101406106B1 (ko) * | 2011-12-19 | 2014-06-13 | 동국제약 주식회사 | 국소 투여용 지속형 치주염 치료제 조성물 |
CN108904460A (zh) * | 2012-02-19 | 2018-11-30 | 奥拉黑尔斯公司 | 用于口腔粘附圆片的碱化金合欢树胶粘合剂 |
KR20170141774A (ko) * | 2015-04-29 | 2017-12-26 | 포어사이트 바이오쎄라퓨틱스, 인코퍼레이티드 | 항바이러스 및 항염증 치료제의 치료 조합물 |
RU2636173C1 (ru) * | 2016-08-03 | 2017-11-21 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СтГМУ Минздрава России) | Способ лечения хронического генерализованного пародонтита средней степени тяжести в стадии обострения |
RU2636185C1 (ru) * | 2016-08-03 | 2017-11-21 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СтГМУ Минздрава России) | Способ лечения хронического генерализованного катарального гингивита в стадии обострения |
BR102018008324A2 (pt) * | 2018-04-25 | 2019-11-05 | Laboratorios Ferring Ltda | composição farmacêutica de uso tópico e processo de fabricação de composição farmacêutica de uso tópico |
CA3099119A1 (en) * | 2018-04-30 | 2019-11-07 | Perfect Day, Inc. | Recombinant milk protein polymers |
WO2020150460A1 (en) * | 2019-01-18 | 2020-07-23 | Milne Iii Donald A | Micronized aspirin formulation |
CN111803468B (zh) * | 2020-06-23 | 2022-12-23 | 黑龙江天龙药业有限公司 | 一种靶向、缓释、成膜抑制病毒、细菌的鼻腔喷膜剂及其制备方法 |
CN115463102B (zh) * | 2022-09-26 | 2023-11-24 | 湖北科益药业股份有限公司 | 一种阿昔洛韦片剂及其制备方法 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58210007A (ja) | 1982-06-02 | 1983-12-07 | Takeda Chem Ind Ltd | 上部「あ」 |
DE3320583A1 (de) | 1983-06-08 | 1984-12-13 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung |
US4849229A (en) | 1984-03-26 | 1989-07-18 | Forest Laboratories, Inc. | Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants |
DE3433239A1 (de) | 1984-09-11 | 1986-03-20 | Bayer Ag, 5090 Leverkusen | Feste arzneizubereitung enthaltend nitrendipin und verfahren zu ihrer herstellung |
IL85538A (en) * | 1987-02-27 | 1991-09-16 | Lilly Co Eli | Sustained release matrix tablet formulations containing hydrophilic and enteric polymers |
US4792452A (en) | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US4915948A (en) | 1987-08-31 | 1990-04-10 | Warner-Lambert Company | Tablets having improved bioadhesion to mucous membranes |
US5160737A (en) | 1988-05-03 | 1992-11-03 | Perio Products Ltd. | Liquid polymer composition, and method of use |
US5330746A (en) | 1988-05-03 | 1994-07-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Dental varnish composition, and method of use |
US5116603A (en) | 1989-01-31 | 1992-05-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Oral antifungal preventative, and method of use |
NZ234587A (en) * | 1989-08-04 | 1991-11-26 | Mcneil Ppc Inc | A chewable pharmaceutical tablet of compressed coated granules |
EP0451433B1 (en) | 1990-04-12 | 1996-10-23 | Janssen Pharmaceutica N.V. | Composition of a bioadhesive sustained delivery carrier for drug administration |
FR2665357B1 (fr) | 1990-07-31 | 1995-03-31 | Aiache Jean Marc | Procede de preparation d'une forme galenique bio-adhesive et forme galenique ainsi preparee. |
GB9318641D0 (en) | 1993-09-08 | 1993-10-27 | Edko Trading Representation | Compositions |
DK0752855T3 (da) | 1994-03-30 | 2000-01-03 | Gs Dev Ab | Anvendelse af fedtsyreestere som bioadhæsive substanser |
SI9500173B (sl) * | 1995-05-19 | 2002-02-28 | Lek, | Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo |
US5766620A (en) | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
US5919489A (en) | 1995-11-01 | 1999-07-06 | Abbott Laboratories | Process for aqueous granulation of clarithromycin |
SI0869772T1 (en) | 1995-12-27 | 2002-04-30 | Janssen Pharmaceutica N.V. | Bioadhesive solid dosage form |
AU6853498A (en) | 1997-04-22 | 1998-11-13 | Nippon Kayaku Kabushiki Kaisha | Flutamide preparations and method for manufacturing the same |
US6248358B1 (en) | 1998-08-25 | 2001-06-19 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets and methods of making and using the same |
SE9803239D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | Composition for the treatment of acute pain |
US6210699B1 (en) * | 1999-04-01 | 2001-04-03 | Watson Pharmaceuticals, Inc. | Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity |
US20030224058A1 (en) * | 2002-05-24 | 2003-12-04 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
WO2002041876A1 (en) * | 2000-11-22 | 2002-05-30 | Lupin Limited | Pharmaceutical composition for controlled release of an active ingredient |
US20020143058A1 (en) * | 2001-01-24 | 2002-10-03 | Taro Pharmaceutical Inductries Ltd. | Process for preparing non-hygroscopic sodium valproate composition |
EP1390015A1 (en) * | 2001-05-31 | 2004-02-25 | Cima Labs Inc. | Taste-masking of highly water-soluble drugs |
FR2827517B1 (fr) * | 2001-07-23 | 2003-10-24 | Bioalliance Pharma | Systemes therapeutiques bioadhesifs a liberation prolongee |
KR20050096950A (ko) * | 2003-01-31 | 2005-10-06 | 오렉쏘 에이비 | 신속-작용 약학 조성물 |
EP1837020A1 (en) | 2006-03-24 | 2007-09-26 | Bioalliance Pharma | Mucosal bioadhesive slow release carrier for delivering active principles |
-
2006
- 2006-03-24 EP EP06290480A patent/EP1837020A1/en not_active Withdrawn
-
2007
- 2007-03-23 WO PCT/IB2007/001662 patent/WO2007110778A2/en active Search and Examination
- 2007-03-23 CA CA2647123A patent/CA2647123C/en active Active
- 2007-03-23 DK DK07734862.1T patent/DK1998750T3/da active
- 2007-03-23 SI SI200730144T patent/SI1998750T1/sl unknown
- 2007-03-23 CN CN2007800105745A patent/CN101410092B/zh active Active
- 2007-03-23 RS RSP-2010/0010A patent/RS51342B/en unknown
- 2007-03-23 AT AT07734862T patent/ATE446743T1/de active
- 2007-03-23 AR ARP070101207A patent/AR060085A1/es not_active Application Discontinuation
- 2007-03-23 MY MYPI20083748A patent/MY150072A/en unknown
- 2007-03-23 ME MEP-2010-13A patent/ME01180B/me unknown
- 2007-03-23 KR KR1020087025055A patent/KR101335185B1/ko active IP Right Grant
- 2007-03-23 AU AU2007231029A patent/AU2007231029B2/en active Active
- 2007-03-23 MX MX2008012186A patent/MX2008012186A/es active IP Right Grant
- 2007-03-23 US US12/225,470 patent/US20090169511A1/en not_active Abandoned
- 2007-03-23 ES ES07734862T patent/ES2335712T3/es active Active
- 2007-03-23 BR BRPI0709057A patent/BRPI0709057C1/pt active IP Right Grant
- 2007-03-23 PL PL07734862T patent/PL1998750T3/pl unknown
- 2007-03-23 EP EP07734862A patent/EP1998750B1/en active Active
- 2007-03-23 DE DE602007002996T patent/DE602007002996D1/de active Active
- 2007-03-23 PT PT07734862T patent/PT1998750E/pt unknown
- 2007-03-23 EP EP09174249A patent/EP2216017A1/en not_active Withdrawn
- 2007-03-23 JP JP2009502254A patent/JP5242548B2/ja active Active
- 2007-03-23 RU RU2008139869/15A patent/RU2420267C2/ru active
-
2008
- 2008-09-09 IL IL193987A patent/IL193987A/en active IP Right Grant
- 2008-09-12 ZA ZA2008/07883A patent/ZA200807883B/en unknown
-
2009
- 2009-02-26 HK HK09101825.0A patent/HK1121692A1/xx unknown
-
2010
- 2010-01-11 CY CY20101100033T patent/CY1109723T1/el unknown
- 2010-01-21 HR HR20100039T patent/HRP20100039T1/hr unknown
- 2010-02-17 US US12/707,369 patent/US8211466B2/en active Active
-
2012
- 2012-06-29 US US13/539,029 patent/US20120326350A1/en not_active Abandoned
- 2012-08-02 US US13/565,653 patent/US8747896B2/en active Active
-
2013
- 2013-07-16 US US13/943,504 patent/US8791127B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100039T1 (hr) | Nosač bioadhezivan za sluznicu za sporo oslobađanje aktivnih elemenata | |
CN101686931A (zh) | 用于制备可咀嚼片剂和锭剂的药物配制剂 | |
NZ556717A (en) | Pharmaceutical compositons useful in the transmucosal administration of drugs using microparticles attached to the surface of larger carrier particles | |
WO2008133330A1 (ja) | 4,5-エポキシモルヒナン誘導体を含有する安定な固形製剤 | |
CN102046147A (zh) | 用于制备快速崩解的片剂的药物配制剂 | |
WO2008086844A2 (en) | Co-precipitate, method for preparing the same and uses thereof | |
CN102905687A (zh) | 包含阿卡波糖的口腔崩解片 | |
de Sá et al. | Design of buccal mucoadhesive tablets: Understanding and development | |
US20130220337A1 (en) | Devices and methods for intravaginal delivery of drugs and other substances | |
US20100087454A1 (en) | Mucosal bioadhesive slow release carrier for delivering active principles | |
CN101590043A (zh) | 一种治疗呼吸道感染的复方制剂及其制备方法 | |
CN101756947A (zh) | 一种治疗哮喘的复方固体制剂 | |
CA2782779C (en) | Mucoadhesive buccal tablets for the treatment of orofacial herpes | |
CN101156856A (zh) | 泛昔洛韦分散片及其制备方法 | |
CN101940563A (zh) | 奥硝唑口腔粘膜缓释贴片及其制备方法 | |
CN112569196A (zh) | 一种克林霉素磷酸酯阴道片及其制备工艺 | |
CN1706412A (zh) | 一种用于治疗妇科疾病的中药泡腾片及其制备方法 | |
CN101658502A (zh) | 一种甲硝唑缓释片及其制备方法 | |
CN100443082C (zh) | 奥硝唑生物粘贴片及其制备方法 | |
CN102600095B (zh) | 一种氨溴索缓释制剂及其制备方法 | |
JP2005525299A5 (hr) | ||
CN104856979A (zh) | 一种甘珀酸钠的口腔贴剂及其制备和应用 | |
CN102488708B (zh) | 镁加铝咀嚼片及其制备方法 | |
EP1475096B1 (en) | Pharmaceutical composition for the treatment of herpes zoster | |
CN117752638A (zh) | 一种抑菌缓释型修复膜及其制备方法 |